Bolezen srpastih celic (pediatrija)
Anemia Management
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (odpre novo okno)
Vir: Lancet Haematol. 2023 ;10(4):e261-71.
Indeksirano: PubMed 36870358
DOI: 10.1016/S2352-3026(22)00405-7
Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (odpre novo okno)
Vir: Eur J Haematol 1996;56(5):326-8.
Indeksirano: PubMed 8641410
https://www.ncbi.nlm.nih.gov/pubmed/8641410 (odpre novo okno)
On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (odpre novo okno)
Vir: Acta Haematol 1995;94(3):128-34.
Indeksirano: PubMed 7502628
https://www.ncbi.nlm.nih.gov/pubmed/7502628 (odpre novo okno)
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (odpre novo okno)
Vir: Haematologica 2006;91(8):1076-83.
Indeksirano: PubMed 16885048
https://www.ncbi.nlm.nih.gov/pubmed/16885048 (odpre novo okno)
Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (odpre novo okno)
Vir: J Obstet Gynaecol 2007;27(1):82-3.
Indeksirano: PubMed 17365469
DOI: 10.1080/01443610601062739
https://www.ncbi.nlm.nih.gov/pubmed/17365469 (odpre novo okno)
The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. (odpre novo okno)
Vir: Am Surg 2009;75(12):1175-8.
Indeksirano: PubMed 19999907
https://www.ncbi.nlm.nih.gov/pubmed/19999907 (odpre novo okno)